Immunotherapy: ALLOGENEIC T-CELL IMMUNOTHERAPY (CE-VST01-JC) FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) USING A HLA-DEFINED PEPTIDE PLATFORM

Gaëtan Thomas(Advanced Fiber Sensors (United States)), Rajiv Khanna(QIMR Berghofer Medical Research Institute), Corey Smith(QIMR Berghofer Medical Research Institute), Leone Beagley, Archana Panikkar(QIMR Berghofer Medical Research Institute), Simon R. Best(Johns Hopkins University), David Porter
Cytotherapy
May 1, 2023
10.1016/s1465-3249(23)00547-9
Cited by 0

Related Papers

Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
|Cancer Discovery|2019|272
Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients.
|Journal of Clinical Pathology|1984|261
Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8+ T-cell function in Hodgkin lymphoma patients
|Blood|2006|250
A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses
|Proceedings of the National Academy of Sciences|2004|235
BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies
|Clinical Microbiology Reviews|2017|226